Vivoo

The Lab Report That Fits in Your Pocket

It's 7 a.m. in San Francisco. You wake up, shuffle to the bathroom, and in ninety seconds, know more about your hydration, vitamin C levels, and pH balance than most people learn in a year of routine checkups. That's the daily reality Vivoo has built for over 100,000 users across more than a hundred countries. And it starts with a stick you dip in your toilet.

Vivoo makes at-home urine test strips. That sentence undersells it considerably. What the company actually makes is a closed-loop health intelligence system - test strips, a smartphone app, and an AI layer - that converts the data your body is already producing into specific, actionable guidance. Not "drink more water." More like: your sodium levels are elevated, your oxidative stress is high, and here's a recipe that addresses both.

The product sits at an intersection that the health industry has mostly ignored: between the clinical precision of a laboratory and the convenience of a consumer app. Vivoo is not a fitness tracker. It doesn't count your steps. It measures what's happening inside your cells and tells you what to do about it before anything goes wrong.

Healthcare Runs on Hindsight

Modern medicine is extraordinarily good at treating things that have already gone wrong. It's considerably less good at catching them first. Most people see a doctor when something hurts. By the time something hurts, the underlying data has been accumulating for months - sometimes years.

The structural irony is that the data is there. Your body generates a continuous stream of biomarker information. Hydration status. Mineral balance. Oxidative load. Ketone production. These numbers shift daily in response to what you eat, how you sleep, how much stress you carry. But outside of a clinical lab, there's been no affordable, repeatable way to read them - until a smartphone with a camera became something nearly everyone carries.

This is the gap Vivoo's founders saw in 2017: a massive, underserved space between the hospital and the habit. The test strips existed - clinical labs had used urine analysis for decades. What didn't exist was a way to connect that data directly to the person it came from, in real time, with personalized context.

Four People, One Very Specific Hunch

Miray Tayfun studied bioengineering at Yildiz Technical University and later completed postgraduate programs at Stanford in go-to-market strategy and diet-gene expression. She had founded companies before - in medical diagnostics, smart homes, co-living. She understood both the science and the sales. When she co-founded Vivoo in 2017, she brought together a team that covered every dimension of what the product needed to be.

CTO Ali Atasever built the image processing algorithm that makes the whole system work - the part that turns a photo taken under inconsistent bathroom lighting into a medically useful data point. COO Gozde Buyukacaroglu brought manufacturing and B2B sales experience. CFO George Radman, a former CEO who had taken a startup through acquisition, handled the financial architecture.

The founding bet was direct: that a smartphone camera, the right algorithm, and a chemically-calibrated strip could replicate what a clinical lab does in a sample collection window - and deliver results before your morning coffee gets cold.

A Strip, a Scan, and Something to Do About It

The core product is deceptively simple. A Vivoo test strip collects a urine sample. You photograph it with your phone. The app's image processing algorithm - trained on thousands of samples, calibrated for lighting variation, tuned for colorimetric precision - reads eight biomarkers simultaneously. Results appear in under ninety seconds.

Those eight markers are: hydration, magnesium, calcium, sodium, vitamin C, ketones, pH, and oxidative stress. Together, they give a picture of how your body is actually performing on a given day - not an estimate, not a fitness score, but biochemical data from the thing you already produce every morning without thinking about it.

The app layer is where the value compounds. Raw biomarker data is useful but inert. Vivoo's AI assistant Welly - fed by a content library of over 5,000 personalized advice pieces developed by actual registered dietitians - translates numbers into behavior. Not generic recommendations, but specific adjustments keyed to your actual results: meal ideas for your hydration profile, supplement timing for your mineral levels, recipe swaps tuned to your pH trends.

When the Data Shows Up at Sam's Club

Vivoo has accumulated a set of proofs that are harder to dismiss than press releases. An 85% customer retention rate in a subscription wellness category where churn is the dominant business problem. Record-breaking sales at Sam's Club - a venue whose core customer base is not usually characterized as early adopters of health technology. A partnership with Otsuka Pharmaceutical, a company whose scientific credibility traces back to the research that gave rise to Gatorade, for exclusive global expansion including the notoriously quality-sensitive Japanese market.

The CES track record is its own data point. In 2023, Vivoo walked away with two CES Innovation Awards. In January 2024, they debuted the Smart UTI Test and won another - this time against a field of products specifically designed to impress people who have seen everything. More than 120 press outlets covered the product at CES 2024.

The retail footprint matters because it says something about who actually uses the product. Vivoo is not sitting in specialty wellness boutiques alongside $80 adaptogen powders. It's at Target, alongside toothpaste. That distribution tells its own story about product simplicity, price accessibility, and consumer confidence in the offering.

Tim Draper, whose portfolio includes Skype, Tesla, and SpaceX, has backed Vivoo from the seed round through the Series B. That level of repeated conviction from a seasoned venture investor carries weight in a market full of wellness products that don't survive their third quarter.

$19.4M and a Legendary VC in the Cap Table

Total confirmed funding: $19.4M. Vivoo's Series B brings its investor roster to over a dozen institutions across venture capital, strategic health, and pharmaceutical categories.

The Shift from Sick Care to Self-Care

Healthcare systems in most developed countries are structurally optimized for illness, not wellness. The economic incentives run toward treatment, not prevention. The result is a population that visits a professional when something is already broken, armed with data that is months or years out of date.

Vivoo's proposition is that the inflection point is now. Smartphone penetration is near-universal. Consumer comfort with health data - wearables, genetic testing, continuous glucose monitors - is at an all-time high. The scientific infrastructure for personalized nutrition has matured to the point where AI can make reliable, evidence-based recommendations from biomarker data in real time. The pieces are all in place for a shift in how ordinary people engage with their own biology.

The company's expansion into women's health is particularly significant. UTI testing, fertility tracking, ovulation monitoring, and reproductive health diagnostics are areas where at-home convenience matters most and clinical access remains uneven. Vivoo's 2024 CES product addressed one of the most common yet underdiagnosed conditions - UTIs - with a device designed for speed, accuracy, and the ability to connect directly to telehealth for same-day treatment.

Back to that bathroom at 7 a.m. in San Francisco. The strip read, the results logged, Welly's meal suggestion for the day already queued up in the app. Ninety seconds of data collection. A day of decisions that are slightly better informed than yesterday's. That accumulation - daily, consistent, personalized - is what Vivoo is actually selling. Not a product. A habit that knows your chemistry.

The laboratory never went anywhere. Vivoo just moved it somewhere more convenient.

Follow, Explore, Shop